Enhance.MD Review 2026
Reviewed August 7, 2026 · Compounded semaglutide and tirzepatide, including a combined semaglutide-plus-tirzepatide protocol. Not FDA-approved.
Visit Enhance.MD WebsiteOverview
Enhance.MD is a compounded GLP-1 service that gets several structural things right and one clinical thing badly wrong. The structure first, because it is genuinely good: every GLP-1 plan includes metabolic lab testing every six months, which almost nothing else in this directory bundles; pricing is flat across all doses with the company stating 'One consistent price from your first dose to your last'; and it publishes the full ladder with first-month and ongoing rates shown separately rather than hiding the step-up. GLP-1 Core (semaglutide) runs $112 for a first month then $212; GLP-1 Advanced (tirzepatide) $180 then $280. It also explains the pharmacology of each tier rather than making bare claims, and is unusually honest about its microdosing product, stating that 'weight loss may occur, but isn't the primary aim'. Then there is GLP-1 Elite. That tier combines semaglutide and tirzepatide in a single protocol at $222 for a first month then $322, described as 'a combination of the Core and Advanced compounds designed to fully activate both GLP-1 and GIP receptors for maximal metabolic benefit', and marketed at 'patients that have plateaued on other GLP-1 medication'. This is the problem. Tirzepatide is already a dual GIP and GLP-1 receptor agonist — it activates both receptors on its own. Adding semaglutide does not unlock a receptor tirzepatide was missing; it stacks a second GLP-1 receptor agonist on top of one that is already there. No approved product combines them, no trial has studied the combination, and the predictable result is additive gastrointestinal toxicity in exactly the patients being targeted.
Medications Offered
Brand-name or compounded: Compounded semaglutide and tirzepatide, including a combined semaglutide-plus-tirzepatide protocol. Not FDA-approved.
- GLP-1 Core — compounded semaglutide, $112 first month then $212/month, all doses
- GLP-1 Advanced — compounded tirzepatide, $180 first month then $280/month, all doses
- GLP-1 Elite — compounded semaglutide PLUS tirzepatide, $222 first month then $322/month, all doses
- Microdosing tirzepatide — $169/month at 1mg/week, shipped every 12 weeks
- NAD+ therapy — $169/month subcutaneous injection
- NAD+ wafers
- All GLP-1 plans include 4 weeks of medication, provider care and 6-monthly metabolic lab testing
Consultation Process
Get started or book a consultation
Enhance.MD offers both a self-serve start and a booked consultation, which is more choice than most competitors provide.
Clinician-led plan selection
Care is described as clinician-led with personalised provider support. This is the point at which to ask directly whether a single agent is appropriate before accepting the combined Elite protocol.
Medication and lab testing
Plans include four weeks of medication and metabolic lab testing every six months — genuinely useful monitoring that most competitors leave to the patient to arrange.
Flat ongoing pricing
After the discounted first month, the ongoing rate applies and holds across all doses. Budget for the ongoing figure, not the introductory one.
Eligibility
- Adults; no published BMI threshold or age range
- Clinician-led assessment before prescribing
- Metabolic lab testing included every six months
- State availability is not published
- Standard GLP-1 contraindications apply — and note the combined protocol compounds gastrointestinal risk
Provider Involvement
Better resourced than most on monitoring. Ongoing provider care is included in every plan and metabolic lab testing is bundled at six-monthly intervals rather than left to the patient — a genuine advantage over the many providers in this directory that require no bloodwork at all. A booked consultation route is offered alongside self-serve signup. What that clinical resourcing does not appear to have prevented is the Elite tier, which suggests commercial product design is running ahead of clinical review.
Lab Requirements
Metabolic lab testing every six months is included in every GLP-1 plan. This is one of the few providers here where monitoring is priced in rather than absent, and it counts strongly in its favour.
Pharmacy Fulfillment
Not named. Enhance.MD describes 'clinician-directed compounds' but does not identify the compounding pharmacy or state its 503A or 503B status. That matters especially for the Elite protocol, since combining two GLP-1 receptor agonists into one compounded product is not something any approved manufacturer does.
Shipping Frequency
GLP-1 plans supply four weeks of medication at a time. Microdosing tirzepatide ships every 12 weeks. No delivery window is published.
Membership Fees vs. Medication Fees
Membership fees
No separate membership fee. The plan price covers medication, provider care and the six-monthly lab testing.
Medication fees
- GLP-1 Core (semaglutide): $112 first month, $212/month ongoing, all doses
- GLP-1 Advanced (tirzepatide): $180 first month, $280/month ongoing, all doses
- GLP-1 Elite (semaglutide + tirzepatide): $222 first month, $322/month ongoing, all doses
- Microdosing tirzepatide: $169/month at 1mg/week
- NAD+ therapy: $169/month
- Promotional codes SUMMER100 and SUMMER50 advertised
Cancellation & Refund Policy
Cancellation
Not published on the pages we reviewed. Establish before subscribing, particularly on 3+ month plans.
Refunds
Not published on the pages we reviewed.
Insurance
Not offered. Enhance.MD is cash-pay and compounded only. If you have GLP-1 coverage, a brand-name provider will cost less.
HSA / FSA
Not stated. Confirm directly.
See our GLP-1 insurance and HSA/FSA guide for how reimbursement works in practice.
Support Services
- Ongoing provider care included in every plan
- Metabolic lab testing every six months
- Booked consultation option as well as self-serve start
- Published health guide and FAQ
State Availability
Not published. Confirm your state before starting.
Pros
- Metabolic lab testing every six months is included in every GLP-1 plan — rare in this market
- Flat pricing across all doses: 'One consistent price from your first dose to your last'
- Publishes a complete price ladder with first-month and ongoing rates stated separately
- Explains the pharmacology of each tier rather than making bare benefit claims
- Ongoing provider care included in the plan price
- Claims 10,000+ patients and offers a booked consultation route
- Honest that its microdosing tier is not primarily a weight-loss product
Cons
- Its 'GLP-1 Elite' tier combines semaglutide AND tirzepatide — two GLP-1 receptor agonists in one protocol
- That combination has no approved product, no trial evidence, and additive gastrointestinal risk
- The stated rationale is pharmacologically confused — tirzepatide already activates both GLP-1 and GIP receptors
- Elite is marketed at patients who have 'plateaued', the group most likely to escalate unsafely
- Compounded only — no brand-name or FDA-approved route
- No named compounding pharmacy, published state list or refund terms
Who Enhance.MD May Be Best For
- Patients who want included lab monitoring and will stay on a single-agent tier
- People who want flat dose-independent pricing with the step-up disclosed upfront
Limitations
- The Elite tier combines two GLP-1 receptor agonists with no evidence base
- Compounded only, with no approved or insurance route
- No named pharmacy, state list or refund terms
- Ongoing rates are substantially higher than the first-month figures
Reputation & Trust
This is a provider we wanted to rate highly. Including metabolic lab testing every six months in every plan is something almost nobody else in this directory does, and it addresses the most common clinical gap we have documented — providers prescribing GLP-1s with no bloodwork whatsoever. Flat pricing across all doses removes the escalation trap. Publishing first-month and ongoing rates separately is honest where competitors bury the step-up. It even declines to oversell its microdosing tier, stating weight loss 'may occur, but isn't the primary aim'. All of that is the behaviour of a serious operation. Then GLP-1 Elite combines semaglutide with tirzepatide and sells it at $322/month to patients who have 'plateaued'. Tirzepatide is a dual GIP and GLP-1 receptor agonist; it already activates both receptors the Elite copy claims the combination is needed to 'fully activate'. Layering semaglutide on top adds a second GLP-1 receptor agonist with no approved precedent, no trial evidence for co-administration, and additive gastrointestinal effects — nausea, vomiting, diarrhoea — plus the theoretical pancreatitis and dehydration risks that scale with GLP-1 exposure. It is the same pattern we found three times over in this queue's men's-health products, where two drugs of one class are combined and marketed as strength: more receptors hit, more benefit implied, no evidence produced. A company that bundles lab testing should know better.
What Makes Enhance.MD Different
- Metabolic lab testing every six months included in every GLP-1 plan
- Flat pricing across all doses with first-month and ongoing rates both published
- Explains the pharmacology of each tier
- Honest that microdosing is not primarily a weight-loss product
Our Verdict
Enhance.MD earns 2.5/5, and it is a frustrating score because most of this service is well built. Metabolic lab testing every six months is included in every GLP-1 plan — almost nothing else in this directory bundles monitoring at all, and it is the single most common clinical gap we have documented. Pricing is flat across all doses, the first-month and ongoing rates are both published rather than the step-up being buried, the pharmacology of each tier is explained, and the microdosing product is honestly labelled as not primarily a weight-loss treatment. Those are the habits of a serious operation. What we cannot get past is GLP-1 Elite: semaglutide combined with tirzepatide, at $322/month, sold to patients who have plateaued as the way to 'fully activate both GLP-1 and GIP receptors'. Tirzepatide already activates both. The combination adds a second GLP-1 receptor agonist with no approved precedent, no trial evidence and predictable additive gastrointestinal toxicity, aimed squarely at the patients most tempted to escalate. It is the same design logic we found in three separate men's-health products in this same queue — combine two drugs of one class, market the count as strength, produce no evidence. Use the Core or Advanced tier and the lab testing makes this a reasonable choice. Do not let anyone sell you Elite without an independent opinion.
Alternatives to Enhance.MD
Peer-reviewed published outcomes and a full brand-name formulary alongside compounded options.
The clearest efficacy and fee disclosure here, with brand-name and non-GLP-1 routes.
If included lab monitoring is what attracts you, Hone builds its whole model around biomarker testing.
One price for all doses with no subscription, on single-agent protocols only.
Compare more options on our best online GLP-1 providers and cheapest GLP-1 programs pages.
Frequently Asked Questions
Is it safe to take semaglutide and tirzepatide together?
We would not do so without a clinician outside the company advising it specifically. Both are GLP-1 receptor agonists — tirzepatide is a dual GIP and GLP-1 agonist, so it already activates both receptors on its own. Combining them adds a second GLP-1 receptor agonist rather than unlocking anything new, and there is no approved product and no trial evidence for co-administration. The predictable consequence is additive gastrointestinal effects — nausea, vomiting, diarrhoea — with the pancreatitis and dehydration risks that scale with GLP-1 exposure. This is informational only; discuss it with an independent clinician.
What does Enhance.MD cost after the first month?
Considerably more than the introductory figure, and to its credit the company publishes both. GLP-1 Core is $112 for the first month then $212/month; GLP-1 Advanced is $180 then $280; GLP-1 Elite is $222 then $322. The ongoing rate applies to all doses, so it does not climb as you titrate. Budget on the ongoing number.
Does the price include lab testing?
Yes, and this is Enhance.MD's strongest feature. Every GLP-1 plan includes metabolic lab testing every six months alongside four weeks of medication and ongoing provider care. A large share of providers in this directory require no bloodwork at all before prescribing, so a service that bundles periodic testing is doing something genuinely better.
What is the microdosing tier for?
Enhance.MD is unusually straight about this: microdosing tirzepatide at 1mg/week is positioned for 'sustainable, longevity-focused benefits over time', with the note that 'weight loss may occur, but isn't the primary aim'. That is more honest than competitors selling microdosing as a cheaper route to the same result. Note microdosing is not an FDA-approved dosing strategy and lacks the outcome evidence behind standard dosing.
Is the medication FDA-approved?
No. Enhance.MD sells compounded semaglutide and tirzepatide, which are not FDA-approved, have not been evaluated for safety, efficacy or quality, and are not therapeutically equivalent to Wegovy, Ozempic, Mounjaro or Zepbound beyond the shared active ingredient. The combined Elite protocol has no approved equivalent of any kind.
Important Notes & Warnings
- This review is informational only and is not medical advice. Consult an independent licensed clinician before starting or changing treatment.
- SAFETY: Enhance.MD's 'GLP-1 Elite' tier combines semaglutide and tirzepatide. Both act on the GLP-1 receptor — tirzepatide is already a dual GIP/GLP-1 agonist. No approved product combines them and no trial has studied co-administration. Expect additive gastrointestinal effects and discuss the combination with a clinician who is not selling it.
- Compounded semaglutide and tirzepatide are NOT FDA-approved and are not therapeutically equivalent to Wegovy, Ozempic, Mounjaro or Zepbound beyond the shared active ingredient.
- Advertised first-month prices are introductory. Ongoing rates are $212, $280 and $322/month respectively.
- Microdosing is not an FDA-approved dosing strategy and lacks the outcome evidence behind standard dosing.
- No compounding pharmacy is named, and no state list or refund terms are published.
- GLP-1 medicines are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2, and in pregnancy.
- Common side effects include nausea, vomiting, diarrhoea, constipation and abdominal pain; serious risks include pancreatitis, gallbladder disease and kidney injury from dehydration. These risks scale with total GLP-1 exposure.
Sources
- Enhance.MD medication and pricing pages, enhance.md (accessed 7 August 2026)
- FDA-approved prescribing information for tirzepatide (a dual GIP and GLP-1 receptor agonist) and semaglutide (a GLP-1 receptor agonist)
Medical Disclaimer
This review is for informational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. GLP-1 medications are prescription drugs with real risks and contraindications. Only a licensed clinician who has evaluated you can decide whether any medication is appropriate. Talk to a healthcare provider before starting, changing, or stopping any treatment, and call emergency services for urgent symptoms.
Facts in this review were compiled from the provider's own public website and public search results as of August 7, 2026. Prices, medication availability, pharmacy partners, and policies change frequently and vary by state — verify everything directly with the provider before purchasing.
This page contains affiliate links. We may earn a commission from qualifying purchases at no additional cost to you.